CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, J.
Right arrow Articles by Vestal, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, J.
Right arrow Articles by Vestal, R. E.

Cell Growth & Differentiation, Vol 8, Issue 6 667-676, Copyright © 1997 by American Association of Cancer Research


ARTICLES

Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene

J Liu, MJ Spence, PM Wallace, K Forcier, I Hellstrom and RE Vestal
Mountain States Medical Research Institute, Boise, Idaho, USA.

Human oncostatin M (OM) is a M(r) 28,000 glycoprotein that has been shown to regulate cell proliferation and differentiation. The biological activities of OM can be mediated by two different heterodimeric receptor complexes, the leukemia inhibitory factor (LIF)/OM shared receptor and the OM-specific receptor. In this study, we have examined the growth-regulatory effect of OM on 10 breast cancer cell lines derived from human tumors. The cellular proliferation of seven of these breast cancer cell lines was inhibited by OM. The three cell lines that did not respond to OM treatment lacked the expression of OM receptors. The growth-inhibitory activity of OM is examined further in the H3922 breast cancer cell line, which expresses the high-affinity OM receptor at a relatively higher level. We found that the cellular proliferation of H3922 cells was induced strongly by extrogenous epidermal growth factor (EGF), EGF-like factor, and basic fibroblast growth factor. The proliferative activities of these growth factors can be abolished totally by cotreatment of H3922 cells with OM. Treatment of H3922 cells with OM for 24 h did not block EGF binding or the induction of EGF receptor tyrosine phosphorylation. This finding suggests that OM interferes with the mitogenic signal at steps distal to the EGF receptor. Examination of proto-oncogene expression demonstrated that OM down-regulates the c-myc gene in H3922 cells. The biological effects reported herein are not shared by the OM-related cytokines interleukin 6 or LIF, as demonstrated by the inability of these proteins to inhibit cell growth or modulate c-myc gene expression in breast cancer cells. Additionally, the high-affinity binding of labeled OM cannot be displaced by LIF. Together, these data suggest that OM is a growth inhibitor for breast cancer cells. The inhibitory activity is mediated predominantly through the OM-specific receptor, and activation of this receptor abrogates growth factor stimulation and down-regulates the c-myc proto-oncogene.


This article has been cited by other articles:


Home page
J Biol ChemHome page
S. Chollangi, T. Mather, K. K. Rodgers, and J. D. Ash
A Unique Loop Structure in Oncostatin M Determines Binding Affinity toward Oncostatin M Receptor and Leukemia Inhibitory Factor Receptor
J. Biol. Chem., September 21, 2012; 287(39): 32848 - 32859.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
O. Larsson, C. Scheele, Z. Liang, J. Moll, C. Karlsson, and C. Wahlestedt
Kinetics of Senescence-associated Changes of Gene Expression in an Epithelial, Temperature-sensitive SV40 Large T Antigen Model
Cancer Res., January 15, 2004; 64(2): 482 - 489.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Hutt and J. W. DeWille
Oncostatin M Induces Growth Arrest of Mammary Epithelium via a CCAAT/enhancer-binding Protein {delta}-dependent Pathway
Mol. Cancer Ther., June 1, 2002; 1(8): 601 - 610.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
H. M. Hermanns, S. Radtke, F. Schaper, P. C. Heinrich, and I. Behrmann
Non-redundant Signal Transduction of Interleukin-6-type Cytokines: THE ADAPTER PROTEIN Shc IS SPECIFICALLY RECRUITED TO THE ONCOSTATIN M RECEPTOR
J. Biol. Chem., December 29, 2000; 275(52): 40742 - 40748.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. M. Hermanns, S. Radtke, C. Haan, H. Schmitz-Van de Leur, J. Tavernier, P. C. Heinrich, and I. Behrmann
Contributions of Leukemia Inhibitory Factor Receptor and Oncostatin M Receptor to Signal Transduction in Heterodimeric Complexes with Glycoprotein 130
J. Immunol., December 15, 1999; 163(12): 6651 - 6658.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
J. Liu, C. Li, T. E. Ahlborn, M. J. Spence, L. Meng, and L. M. Boxer
The Expression of p53 Tumor Suppressor Gene in Breast Cancer Cells Is Down-Regulated by Cytokine Oncostatin M
Cell Growth Differ., October 1, 1999; 10(10): 677 - 683.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
T. Jia, Y. E. Liu, J. Liu, and Y. E. Shi
Stimulation of Breast Cancer Invasion and Metastasis by Synuclein {{gamma}}
Cancer Res., February 1, 1999; 59(3): 742 - 747.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
H. M. Hermanns, S. Radtke, F. Schaper, P. C. Heinrich, and I. Behrmann
Non-redundant Signal Transduction of Interleukin-6-type Cytokines: THE ADAPTER PROTEIN Shc IS SPECIFICALLY RECRUITED TO THE ONCOSTATIN M RECEPTOR
J. Biol. Chem., December 29, 2000; 275(52): 40742 - 40748.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1997 by the American Association of Cancer Research.